Home » Topics » Cardiovascular, BioWorld Science

Cardiovascular, BioWorld Science
RSS

New C5a-R antagonists identified at Idorsia Pharmaceuticals

Aug. 12, 2019

Phase III results for fixed-dose combination of bempedoic acid plus ezetimibe

Aug. 12, 2019

Risk assessment for long QT syndrome

Aug. 9, 2019

Idorsia Pharmaceuticals describes C5aR antagonists

Aug. 8, 2019

Where TH2 cells go, blood vessels are built

Aug. 8, 2019

Idorsia Pharmaceuticals identifies C5aR antagonists

Aug. 5, 2019

Myocardial ischemia/reperfusion injury is reduced by prostacyclin analogue-loaded nanoparticles

Aug. 2, 2019

Development of a new class of indazole-based MRA by modern CH functionalization chemistry

Aug. 1, 2019

Mezzion reports promising topline data from phase III FUEL study of udenafil

July 31, 2019

Selective CaMKII inhibition by gene therapy suppresses arrhythmias in CPVT models

July 30, 2019

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for July 9, 2026.
‘Target-high but uptake-defective’ state identified in ADC resistance
BioWorld
Separate research teams have reported new insights into resistance mechanisms to the antibody-drug conjugate (ADC) Padcev (enfortumab vedotin, Astellas Pharma...
Hyperexcitability may be joint problem in epilepsy, dementia
BioWorld
The majority of epilepsies are developmental disorders that start in childhood. But there is a large minority that starts in late adulthood. And increasingly,...
Neurovalens granted FDA approval for PTSD therapy for US veterans
BioWorld
Veterans in the U.S. suffering from post-traumatic stress disorder (PTSD) now have access to Neurovalens Ltd.’s Modius Spero, a wearable neuromodulation device,...
FENS 2026: Shedding light on the sheddome
BioWorld
At the recently opened FENS Forum 2026 in Barcelona – the Federation of European Neuroscience Societies’ flagship congress and Europe’s largest neuroscience...